Articles
Trademarks in the medical sphere: Practice, examination and obstacles for registration in Russia, Ukraine and the CIS
Pharmaceutical industry in Russia, Ukraine and in other CIS countries can be considered one of the most complex industries with a view to the management of intellectual property, as it involves complicated legal, regulatory, linguistic and marketing considerations.
It is...
Articles
Older Users and eCOA: They’re Ready, Are You?
“I have a system. The charger is always plugged in in the same place and I charge it every night, overnight.” This may sound like the mantra of a 14-year old boy, one who ensures his phone has the...
Articles
The year that was and the year that will be!!
Pharma Industry Leaders Views on Trends and Innovations of 2019 and Predictions for 2020.
The Pharmaceutical Industry has been witness to an enhanced outlook in 2019. There have been significant developments and new avenue evolutions which have changed the way...
Articles
Start “Early” in Healthy for timely results for your dosage form
Early phase bioequivalence studies are/can be conducted on all USFDA Orange book approved list of dosage forms based on submission requirements by pharmaceutical companies This has been a market trend for more than 2 decades.
USFDA Orange book lists nearly...
Articles
Managing Risks With Potent Pharmaceutical Products
As a noticeable shift occurs in the pharmaceutical industry from blockbuster drugs to smaller patient populations, there is an increased focus on targeted therapies in specialized areas, such as oncology, where potent compounds serve a key role in patient...
Articles
Integrating biological safety cabinets into the cGMP environment to support aseptic processing
Pharmaceutical manufacturers have a duty to deliver consistently safe and effective medicines, and a fundamental part of this is ensuring products do not contain harmful biological contaminants. One approach that is widely used to guarantee drugs are free from...
Articles
Redefining outsourcing: How the CDMO sector is reshaping its business
An ageing population, patent expirations, growth of disease prevalence, and expensive breakthrough therapies are driving demand for the development of many new pharmaceutical products. These growing pressures mean that pharmaceutical developers are faced with rising R&D costs and the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.